NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis.

The oncogenicity of neural precursor cell-expressed developmentally down-regulated 9 (NEDD9) has been demonstrated in multiple cancer types. However, the prognostic value of NEDD9 in some solid cancers remains controversial. Thus, this meta-analysis was conducted to evaluate the relationship between NEDD9 expression survival rates in solid tumors. Our meta-analysis included studies searched from various search engines with specific inclusion criteria and exclusion criteria. Combined HRs for overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS) or recurrence-free survival (RFS) or cancer-specific survival (CSS) were assessed using fixed-effects and random-effects models. The source of heterogeneity was identified by subgroup analysis. Additionally, publication bias was assessed using funnel plot and Egger's regression asymmetry test. Eighteen studies with a total of 2,476 patients were retrieved for analysis. Pooled HRs and 95% CIs were calculated. Both OS (HR=1.82; 95% CI: 1.43-2.31) and DFS/PFS/RFS/CSS (HR=2.54; 95% CI: 1.93-3.33) indicated that NEDD9 overexpression is associated with poor OS in cancer patients with solid tumors. NEDD9 overexpression might be a potential marker to predict prognosis in solid cancer patients.